Pelvic Inflammatory Disease
|
Quite a few conditions
are improved by adding Wobenzym to the treatment plan. We
see it used with various forms of both acute and chronic
pelvic inflammatory disease. It is also very effective
therapy for the management of fibrocystic breast disease,
especially since it does not not interfere with already
upset hormonal balance that typically accompanies
fibrocystic breast disease. From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: HORMONES & WOBENZYM® |
What
the literature says about Systemic Enzyme Support and:
Pelvic Inflammatory Disease
Adnexitis, Salpingitis, Salpingoophoritis, Oophoritis
Wobenzym® in the Treatment of Chronic Pelvic Inflammatory
Disease.
Friedrich F. Wobenzym® in the Treatment of Chronic Pelvic Inflammatory Disease. Germany Report provides through: PHARMASCRIPT, Kathi-Kobus-Steig 1, W-8190. Study Number: MU-89210.
Summary
This study was carried out as a randomised, double blind clinical
trial with parallel groups and active control. The aim was to prove,
whether efficacy and tolerance of WOBENZYM® are comparable to
Diclofenac in patients with chronic pelvic inflammatory disease
(PID).
44
female patients with anamnestically and laparoscopically verified
chronic PID were taken into this study. The data of 40 patients were
evaluable.
The
study was carried out by Univ. Prof. Prim. Florian Friedrich, M.D.,
City Hospital, Spitalgasse 10, A-3580 Horn, Austria.
The
patients of the enzyme group were given 5 enteric coated tablets
WOBENZYM® and 2 capsules placebo t.i.d., the patients of the
Diclofenac group 5 tablets placebo and 2 capsules with 50 mg
Diclofenac each t.i.d. ("double dummy" method). The drugs were
randomised and blinded. Duration of therapy was 3 weeks.At start of
the trial the patients were comparable with response to age, height,
weight, pain on motion, pain under pressure, abdominal defence,
abdominal pain, micturition difficulties and painful defecation.
Main criterion for statistical evaluation was a sum score computed
from the symptoms gynecological palpation (pain under motion, pain
under pressure, abdominal defence), ESR score and WBC score at end
of therapy.
Secondary criteria were the objective and subjective variables
according to the CRF like general condition (abdominal pain,
micturition difficulties, painful defecation) and C-reactive
protein. The statistical tests were calculated on equivalence
between both treatment groups.
There was no statistical difference between the both groups after 3
weeks of therapy in the main and secondary criteria (p > 0,05).
The
physician judged the efficacy of the therapy after three weeks in
the enzyme group as 1.9 ("good") and in the Diclofenac group as 1.6
("good"); the judgement of the patients was 2.0 ("good") in each
group. The tolerance of the tested drugs was judged by the physician
as 1.9 ("good") in the enzyme group and as 1.7 ("good") in the
Diclofenac group, by the patients as 2.1 ("good") in the enzyme
group and as 1.8 ("good") in the Diclofenac group.Adverse events
were documented in three patients (13.6%) of the Diclofenac group
only. Two of the adverse events were gastro-intestinal comp1aints,
in one case a blepharedema was documented. The onset was between the
1st and the 8th day of therapy and the mean duration was 7.3 days.
Severity of the adverse events was 2.0 ("moderate") on average.
Poster Reference Number 36.
Therapy of adnexitis - enhancement of the basic antibiotic therapy
with hydrolytic enzymes.
Dittmar F.-W.1, Weissenbacher E. R.2. Therapy
of adnexitis - enhancement of the basic antibiotic therapy with
hydrolytic enzymes. International Journal of Experimental and
Clinical Chemotherapy 1992: Vol. 5, No. 2, pp. 73-81. WE 12 (5-03-2)
= WE 44 (5-04-2) nìm. [Czech]1 Department of Obstetrics and Gynecology, District Hospital
Starnberg, Teaching Hospital of the Ludwig-Maximilians-University
Munich, W-8130 Starnberg, FRG2 Gynecologic Clinic, Clinic Center Großhadern,
Ludwig-Maximilians-University Munich, W-8000 Munich 70, FRG
Abstract
A
total of 56 patients were recruited to a randomized double blind
study (28 to the enzymes and placebo group, respectively) and
treated for a period of 28 days in order to evaluate the
effectiveness and tolerance of an enzyme combination preparation as
adjuvant of the initial 6-day basic antibiotic treatment.
At
the beginning of the investigation there were no differences between
the enzymes and the placebo group regarding the parameters
characterizing the process of recovery. At the end, however, such
differences were observed: body temperature in the enzymes group
37.0°C, in the placebo group 37.2°C, p = 0.021; WBC in the enzymes
group 8,800/m l, in the placebo group 10,100/m l, p = 9.52 x 10-6;
ESR after 1 h 14.8 mm/h and 19.5 mm/h in the enzymes and placebo
group, respectively, p = 0.003; score for palpable tumors in the
enzymes group 1.0 ("more resistant to touch than normal on one
side") and 3.0 in the placebo group ("bilateral resistance to
touch"), p = 1.28 x 10-7; score for tenderness on pressure in the
enzymes group 0 (nothing abnormal detected) and 2 in the placebo
group (uterus and adnexa), p = 4.42 x 10-7; score for vaginal
discharge in the enzymes group 0 ("white/normal") and 1 in the
placebo group ("slightly purulent and/or sanguineous"), p = 1.39 x
10-6.
The
adnexitis score, defined as major criterion of effectiveness, gave
corresponding results: with comparable baseline values (enzymes =
12.2, placebo = 11.3, p = 0.08) it was 2.6 in the enzymes group
(subacute adnexitis) and 7.7 in the placebo group (moderate
adnexitis) at the end of therapy (p = 7.45 x 10-7).
The
results of this study suggest that the enzyme combination
preparation used is effective as adjuvant of basic antibiotic
treatment in acute adnexitis. There were no side effects in either
group.
Key
words: Therapy of adnexitis - adjuvant enzyme therapy - enzyme
combination preparation vs. placebo - antiinflammatory effect
Poster Reference Number 37.
Systemic enzyme therapy in the treatment of chronic salpingitis and
infertility.
Ivaniyta L.I., Ivaniyta S.O., Kornatskaya A.G., Belis N.I.,
Kondratiyk. Systemic enzyme therapy in the treatment of chronic
salpingitis and infertility. Farm. Zh. (Kiev) 1998, No. 2, pp.
89-92.
30
women, mean age 26.5 years, with chronic salpingitis and infertility
were observed. 18 women suffered from primary infertility, 12 from
secondary one. 21 patients were previously treated (antiinflammatory,
hormonal therapy). 27 patients were diagnosed with unilateral
salpingitis, 3 with bilateral one.Treatment started after activation
of chronic inflammatory process. First, pyrogenal was administered,
followed by antibacterial, anticandidous, desensibilization, and
vitamin therapy. Together with antibiotics, Wobenzym was
administered at the dose of 5 dragees 3 times a day for 10 days.
Patients in the control group received the same therapy without
Wobenzym.
Already after 5-6 days of Wobenzym treatment, an improvement of
patients' condition was observed. Frequency and intensity of
abdominal pain and in 86.4 % normalization of body temperature,
appetite and intestinal function was seen. Positive changes of
inflammatory signs were found after treatment - decreased
infiltration, disappearance of pain on palpation. Positive status
was verified also by blood parameters: leukocyte count decreased
from 8.0 ± 0.3 x 109 to 6.3 ± 0.1 x 109. Sedimentation normalized
and concentration of C-reactive protein decreased under Wobenzym
treatment. Above described parameters did not change in the control
group.
Poster Reference Number 61.
Wobenzym in complex therapy of actinomycosis of abdominal cavity and
small pelvis in women.
Mirzabalaeva A.K., Klimko N.N., Yarobkova N.D. Wobenzym
in complex therapy of actinomycosis of abdominal cavity and
small pelvis in women.
Problemy medicinskoj mykologii 1999, Vol. 1., No. 1, pp. 45-50.
[Russian, Czech]
36
patients in the age from 18 to 49 years (average age in years -
38,8) were treated. Clinical variants of actinomycosis have been
manifested by endometritis, salpingitis, salpingoophoritis or liver
abscesses. The diagnosis was established basing on hystological
research of endometrium smears and bioptat with the detection of
specific actinomycotic granuloma. The therapy with the wide spectrum
antibiotics was carried out to all the patients; 14 patients
received wobenzym during 6 weeks – 5 dragees 3 times per day with
antibacterial therapy. The control group included 22 patients.
Patients in comparison groups did not differ by age, duration and
localization of disease.
Average duration of treatment of patients with wobenzym was of 4,5
months and 8,5 months in control group. In patients receiving
wobenzym the repeated surgical operations were not carried out, in
control group the frequency of repeated operations was of 31,8 %.
Key
words: actinomycosis, actinomycotic granuloma, wobenzym.